Phathom Pharmaceuticals(US:PHAT) Globenewswireยท2025-04-01 20:15Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [4] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [4] Leadership Appointment - Steven Basta has been appointed as President and Chief Executive Officer of Phathom Pharmaceuticals [1] - The Board of Directors approved inducement awards in connection with Mr. Basta's appointment [1] Inducement Awards - Mr. Basta will receive a non-qualified stock option to purchase 1,085,000 shares of Phathom common stock, with 25% vesting on April 1, 2026, and the remainder vesting in 36 equal monthly installments thereafter [2] - Additionally, Mr. Basta will be granted 360,000 performance stock units tied to specific stock price hurdles and a service-based vesting requirement, along with 180,000 performance stock units tied to annual Company revenue targets over a three-year performance period ending December 31, 2027 [2][3] - The performance stock units will be granted under the Inducement Plan upon the filing of a Form S-8 registration statement [3]